CRNX
Crinetics Pharmaceuticals, Inc. Healthcare - Biotechnology Investor Relations →
Crinetics Pharmaceuticals, Inc. (CRNX) closed at $39.02 as of 2026-05-01, trading 14.2% above its 200-week moving average of $34.15. The stock moved further from the line this week, up from 12.6% last week. With a 14-week RSI of 28, CRNX is in oversold territory.
Trading volume is running at 1.5x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.95 ratio) is neutral — neither side is clearly dominating.
Over the past 358 weeks of data, CRNX has crossed below its 200-week moving average 14 times. On average, these episodes lasted 13 weeks. Historically, investors who bought CRNX at the start of these episodes saw an average one-year return of +26.4%.
With a market cap of $4.1 billion, CRNX is a mid-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -40.2%. The stock trades at 3.8x book value.
Share count has increased 77.4% over three years, indicating dilution.
Over the past 6.9 years, a hypothetical investment of $100 in CRNX would have grown to $156, compared to $272 for the S&P 500. CRNX has returned 6.6% annualized vs 15.6% for the index, underperforming the broader market over this period.
Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: CRNX vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After CRNX Crosses Below the Line?
Across 14 historical episodes, buying CRNX when it crossed below its 200-week moving average produced an average return of +29.9% after 12 months (median -3.0%), compared to +11.6% for the S&P 500 over the same periods. 45% of those episodes were profitable after one year. After 24 months, the average return was +85.2% vs +36.0% for the index.
Each line shows $100 invested at the moment CRNX crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
CRNX has crossed below its 200-week MA 14 times with an average 1-year return of +26.4% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Jun 2019 | Dec 2019 | 27 | 40.0% | -30.4% | +56.1% |
| Jan 2020 | Aug 2021 | 82 | 45.2% | -40.3% | +64.0% |
| Oct 2021 | Oct 2021 | 2 | 4.4% | -10.8% | +100.1% |
| Jan 2022 | Mar 2022 | 10 | 15.5% | +4.4% | +105.7% |
| Apr 2022 | Jul 2022 | 10 | 18.6% | -3.8% | +92.0% |
| Jul 2022 | Aug 2022 | 2 | 4.4% | -4.1% | +100.1% |
| Aug 2022 | Aug 2022 | 1 | 2.6% | -12.5% | +99.9% |
| Sep 2022 | Jan 2023 | 17 | 15.8% | +58.7% | +114.9% |
| Mar 2023 | Apr 2023 | 7 | 17.9% | +144.7% | +125.8% |
| Jun 2023 | Sep 2023 | 12 | 14.8% | +146.2% | +110.8% |
| Mar 2025 | Apr 2025 | 2 | 8.6% | +38.5% | +45.1% |
| May 2025 | May 2025 | 1 | 0.2% | N/A | +31.1% |
| Jun 2025 | Jul 2025 | 2 | 1.0% | N/A | +30.2% |
| Jul 2025 | Aug 2025 | 2 | 11.4% | N/A | +40.2% |
| Average | 13 | — | +26.4% | — |
Frequently Asked Questions
Is CRNX below its 200-week moving average?
No. Crinetics Pharmaceuticals, Inc. (CRNX) is currently 14.2% above its 200-week moving average of $34.15. It would need to fall to $34.15 to cross below the line.
What is CRNX's 200-week moving average price?
Crinetics Pharmaceuticals, Inc.'s 200-week moving average is $34.15 as of 2026-05-01. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when CRNX drops below its 200-week moving average?
CRNX has crossed below its 200-week moving average 14 times in our data. On average, buying at that moment produced a one-year return of +26.4%. These dips have historically been decent entry points. These episodes lasted 13 weeks on average.
Is CRNX a good value right now?
Here's what our data says about CRNX as of 2026-05-01: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 28 (oversold). Free cash flow is currently negative. Return on equity is -40.2%. Price-to-book is 3.8x. This is not a buy or sell recommendation — always do your own research.
How does CRNX compare to the S&P 500?
Over the past 6.9 years, $100 invested in CRNX would have grown to $156, compared to $272 for the S&P 500. That's 6.6% annualized vs 15.6% for the index. CRNX has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-05-01